sirnas against itga3 Search Results


sirnas against itga3  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology sirnas against itga3
( A ) ELISA assessing the binding specificity of 2E7 scFv-Fc binding to the ITGA3B1 heterodimer and its individual subunits ( <t>ITGA3</t> and ITGB1 ), as well as to the structurally related integrin complex ITGA6B4 and its subunits ( ITGA6 and ITGB4 ). HuIgG and BSA were included as negative controls. Data represent the mean ± SD from three technical replicates. A 450 , absorbance at 450 nm. ( B ) Dose-dependent binding of 2E7 scFv-Fc to immobilized ITGA3 , ITGB1 , and ITGA3B1 , as determined by ELISA. ( C ) Flow cytometry analysis of HEK293 cells transiently transfected with ITGA3 , ITGB1 , or both. ( D ) Flow cytometry of MDA-MB-231 cells following siRNA knockdown of ITGA3 , ITGB1 , or both ITGA3 and ITGB1 . ( E ) SPR sensorgrams showing 2E7 scFv-Fc binding to recombinant ITGA3B1 in the presence of either divalent cations or EDTA. Data shown are representative of three independent experiments.
Sirnas Against Itga3, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirnas+against+itga3/pmc12757053-217-1-18?v=Santa+Cruz+Biotechnology
Average 93 stars, based on 1 article reviews
sirnas against itga3 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
nontargeting control sirna  (Santa Cruz Biotechnology)
96
Santa Cruz Biotechnology nontargeting control sirna
( A ) ELISA assessing the binding specificity of 2E7 scFv-Fc binding to the ITGA3B1 heterodimer and its individual subunits ( ITGA3 and ITGB1 ), as well as to the structurally related integrin complex ITGA6B4 and its subunits ( ITGA6 and ITGB4 ). HuIgG and BSA were included as negative controls. Data represent the mean ± SD from three technical replicates. A 450 , absorbance at 450 nm. ( B ) Dose-dependent binding of 2E7 scFv-Fc to immobilized ITGA3 , ITGB1 , and ITGA3B1 , as determined by ELISA. ( C ) Flow cytometry analysis of HEK293 cells transiently transfected with ITGA3 , ITGB1 , or both. ( D ) Flow cytometry of MDA-MB-231 cells following <t>siRNA</t> knockdown of ITGA3 , ITGB1 , or both ITGA3 and ITGB1 . ( E ) SPR sensorgrams showing 2E7 scFv-Fc binding to recombinant ITGA3B1 in the presence of either divalent cations or EDTA. Data shown are representative of three independent experiments.
Nontargeting Control Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirnas+against+itga3/pmc12757053-217-11-18?v=Santa+Cruz+Biotechnology
Average 96 stars, based on 1 article reviews
nontargeting control sirna - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier
itgb1  (Santa Cruz Biotechnology)
93
Santa Cruz Biotechnology itgb1
( A ) ELISA assessing the binding specificity of 2E7 scFv-Fc binding to the ITGA3B1 heterodimer and its individual subunits ( ITGA3 and <t>ITGB1</t> ), as well as to the structurally related integrin complex ITGA6B4 and its subunits ( ITGA6 and ITGB4 ). HuIgG and BSA were included as negative controls. Data represent the mean ± SD from three technical replicates. A 450 , absorbance at 450 nm. ( B ) Dose-dependent binding of 2E7 scFv-Fc to immobilized ITGA3 , ITGB1 , and ITGA3B1 , as determined by ELISA. ( C ) Flow cytometry analysis of HEK293 cells transiently transfected with ITGA3 , ITGB1 , or both. ( D ) Flow cytometry of MDA-MB-231 cells following siRNA knockdown of ITGA3 , ITGB1 , or both ITGA3 and ITGB1 . ( E ) SPR sensorgrams showing 2E7 scFv-Fc binding to recombinant ITGA3B1 in the presence of either divalent cations or EDTA. Data shown are representative of three independent experiments.
Itgb1, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sirnas+against+itga3/pmc12757053-217-6-18?v=Santa+Cruz+Biotechnology
Average 93 stars, based on 1 article reviews
itgb1 - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier
human egfr specific sirna oligo  (Santa Cruz Biotechnology)
93
  Buy from Supplier

Image Search Results


( A ) ELISA assessing the binding specificity of 2E7 scFv-Fc binding to the ITGA3B1 heterodimer and its individual subunits ( ITGA3 and ITGB1 ), as well as to the structurally related integrin complex ITGA6B4 and its subunits ( ITGA6 and ITGB4 ). HuIgG and BSA were included as negative controls. Data represent the mean ± SD from three technical replicates. A 450 , absorbance at 450 nm. ( B ) Dose-dependent binding of 2E7 scFv-Fc to immobilized ITGA3 , ITGB1 , and ITGA3B1 , as determined by ELISA. ( C ) Flow cytometry analysis of HEK293 cells transiently transfected with ITGA3 , ITGB1 , or both. ( D ) Flow cytometry of MDA-MB-231 cells following siRNA knockdown of ITGA3 , ITGB1 , or both ITGA3 and ITGB1 . ( E ) SPR sensorgrams showing 2E7 scFv-Fc binding to recombinant ITGA3B1 in the presence of either divalent cations or EDTA. Data shown are representative of three independent experiments.

Journal: Science Advances

Article Title: Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer

doi: 10.1126/sciadv.ady0041

Figure Lengend Snippet: ( A ) ELISA assessing the binding specificity of 2E7 scFv-Fc binding to the ITGA3B1 heterodimer and its individual subunits ( ITGA3 and ITGB1 ), as well as to the structurally related integrin complex ITGA6B4 and its subunits ( ITGA6 and ITGB4 ). HuIgG and BSA were included as negative controls. Data represent the mean ± SD from three technical replicates. A 450 , absorbance at 450 nm. ( B ) Dose-dependent binding of 2E7 scFv-Fc to immobilized ITGA3 , ITGB1 , and ITGA3B1 , as determined by ELISA. ( C ) Flow cytometry analysis of HEK293 cells transiently transfected with ITGA3 , ITGB1 , or both. ( D ) Flow cytometry of MDA-MB-231 cells following siRNA knockdown of ITGA3 , ITGB1 , or both ITGA3 and ITGB1 . ( E ) SPR sensorgrams showing 2E7 scFv-Fc binding to recombinant ITGA3B1 in the presence of either divalent cations or EDTA. Data shown are representative of three independent experiments.

Article Snippet: Target-specific siRNAs against ITGA3 (sc-35684) and ITGB1 (sc-35674), along with a nontargeting control siRNA (sc-37007), were obtained from Santa Cruz Biotechnology (Dallas, TX).

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Flow Cytometry, Transfection, Knockdown, Recombinant

( A ) ITGA3 mRNA expression in normal bladder tissues ( n = 18) and primary bladder tumors ( n = 408) based on TCGA data. ( B ) ITGA3 expression across consensus molecular subtypes of bladder cancer from five aggregated clinical cohorts. ( C ) Representative multiplex immunofluorescence images of TMA cores stained for ITGA3 (green), ITGB1 (red), and nuclei [DAPI (4′,6-diamidino-2-phenylindole), blue] of primary bladder carcinomas and normal tissues. Scale bars, 100 μm. ( D to F ) Quantification of ITGA3 expression in tumor versus normal tissues: fluorescence intensity (D), percentage of ITGA3 -positive cells (E), and H -scores (F). **** P < 0.0001.

Journal: Science Advances

Article Title: Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer

doi: 10.1126/sciadv.ady0041

Figure Lengend Snippet: ( A ) ITGA3 mRNA expression in normal bladder tissues ( n = 18) and primary bladder tumors ( n = 408) based on TCGA data. ( B ) ITGA3 expression across consensus molecular subtypes of bladder cancer from five aggregated clinical cohorts. ( C ) Representative multiplex immunofluorescence images of TMA cores stained for ITGA3 (green), ITGB1 (red), and nuclei [DAPI (4′,6-diamidino-2-phenylindole), blue] of primary bladder carcinomas and normal tissues. Scale bars, 100 μm. ( D to F ) Quantification of ITGA3 expression in tumor versus normal tissues: fluorescence intensity (D), percentage of ITGA3 -positive cells (E), and H -scores (F). **** P < 0.0001.

Article Snippet: Target-specific siRNAs against ITGA3 (sc-35684) and ITGB1 (sc-35674), along with a nontargeting control siRNA (sc-37007), were obtained from Santa Cruz Biotechnology (Dallas, TX).

Techniques: Expressing, Multiplex Assay, Immunofluorescence, Staining, Fluorescence

( A ) ELISA assessing the binding specificity of 2E7 scFv-Fc binding to the ITGA3B1 heterodimer and its individual subunits ( ITGA3 and ITGB1 ), as well as to the structurally related integrin complex ITGA6B4 and its subunits ( ITGA6 and ITGB4 ). HuIgG and BSA were included as negative controls. Data represent the mean ± SD from three technical replicates. A 450 , absorbance at 450 nm. ( B ) Dose-dependent binding of 2E7 scFv-Fc to immobilized ITGA3 , ITGB1 , and ITGA3B1 , as determined by ELISA. ( C ) Flow cytometry analysis of HEK293 cells transiently transfected with ITGA3 , ITGB1 , or both. ( D ) Flow cytometry of MDA-MB-231 cells following siRNA knockdown of ITGA3 , ITGB1 , or both ITGA3 and ITGB1 . ( E ) SPR sensorgrams showing 2E7 scFv-Fc binding to recombinant ITGA3B1 in the presence of either divalent cations or EDTA. Data shown are representative of three independent experiments.

Journal: Science Advances

Article Title: Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer

doi: 10.1126/sciadv.ady0041

Figure Lengend Snippet: ( A ) ELISA assessing the binding specificity of 2E7 scFv-Fc binding to the ITGA3B1 heterodimer and its individual subunits ( ITGA3 and ITGB1 ), as well as to the structurally related integrin complex ITGA6B4 and its subunits ( ITGA6 and ITGB4 ). HuIgG and BSA were included as negative controls. Data represent the mean ± SD from three technical replicates. A 450 , absorbance at 450 nm. ( B ) Dose-dependent binding of 2E7 scFv-Fc to immobilized ITGA3 , ITGB1 , and ITGA3B1 , as determined by ELISA. ( C ) Flow cytometry analysis of HEK293 cells transiently transfected with ITGA3 , ITGB1 , or both. ( D ) Flow cytometry of MDA-MB-231 cells following siRNA knockdown of ITGA3 , ITGB1 , or both ITGA3 and ITGB1 . ( E ) SPR sensorgrams showing 2E7 scFv-Fc binding to recombinant ITGA3B1 in the presence of either divalent cations or EDTA. Data shown are representative of three independent experiments.

Article Snippet: Target-specific siRNAs against ITGA3 (sc-35684) and ITGB1 (sc-35674), along with a nontargeting control siRNA (sc-37007), were obtained from Santa Cruz Biotechnology (Dallas, TX).

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Flow Cytometry, Transfection, Knockdown, Recombinant

Cytotoxicity of the 2E7 ADC in human bladder cancer cell lines (UM-UC-3, CoCaB1, SCaBER, SW780, UM-UC-9, and HT-1376) following a 72-hour treatment. IC 50 values and percent inhibition were determined using cell viability assays. Treatments included the 2E7 ADC, unconjugated 2E7 Ab, and a nontargeting IgG-MMAE control ADC.

Journal: Science Advances

Article Title: Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer

doi: 10.1126/sciadv.ady0041

Figure Lengend Snippet: Cytotoxicity of the 2E7 ADC in human bladder cancer cell lines (UM-UC-3, CoCaB1, SCaBER, SW780, UM-UC-9, and HT-1376) following a 72-hour treatment. IC 50 values and percent inhibition were determined using cell viability assays. Treatments included the 2E7 ADC, unconjugated 2E7 Ab, and a nontargeting IgG-MMAE control ADC.

Article Snippet: Target-specific siRNAs against ITGA3 (sc-35684) and ITGB1 (sc-35674), along with a nontargeting control siRNA (sc-37007), were obtained from Santa Cruz Biotechnology (Dallas, TX).

Techniques: Inhibition, Control

( A ) ELISA assessing the binding specificity of 2E7 scFv-Fc binding to the ITGA3B1 heterodimer and its individual subunits ( ITGA3 and ITGB1 ), as well as to the structurally related integrin complex ITGA6B4 and its subunits ( ITGA6 and ITGB4 ). HuIgG and BSA were included as negative controls. Data represent the mean ± SD from three technical replicates. A 450 , absorbance at 450 nm. ( B ) Dose-dependent binding of 2E7 scFv-Fc to immobilized ITGA3 , ITGB1 , and ITGA3B1 , as determined by ELISA. ( C ) Flow cytometry analysis of HEK293 cells transiently transfected with ITGA3 , ITGB1 , or both. ( D ) Flow cytometry of MDA-MB-231 cells following siRNA knockdown of ITGA3 , ITGB1 , or both ITGA3 and ITGB1 . ( E ) SPR sensorgrams showing 2E7 scFv-Fc binding to recombinant ITGA3B1 in the presence of either divalent cations or EDTA. Data shown are representative of three independent experiments.

Journal: Science Advances

Article Title: Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer

doi: 10.1126/sciadv.ady0041

Figure Lengend Snippet: ( A ) ELISA assessing the binding specificity of 2E7 scFv-Fc binding to the ITGA3B1 heterodimer and its individual subunits ( ITGA3 and ITGB1 ), as well as to the structurally related integrin complex ITGA6B4 and its subunits ( ITGA6 and ITGB4 ). HuIgG and BSA were included as negative controls. Data represent the mean ± SD from three technical replicates. A 450 , absorbance at 450 nm. ( B ) Dose-dependent binding of 2E7 scFv-Fc to immobilized ITGA3 , ITGB1 , and ITGA3B1 , as determined by ELISA. ( C ) Flow cytometry analysis of HEK293 cells transiently transfected with ITGA3 , ITGB1 , or both. ( D ) Flow cytometry of MDA-MB-231 cells following siRNA knockdown of ITGA3 , ITGB1 , or both ITGA3 and ITGB1 . ( E ) SPR sensorgrams showing 2E7 scFv-Fc binding to recombinant ITGA3B1 in the presence of either divalent cations or EDTA. Data shown are representative of three independent experiments.

Article Snippet: Target-specific siRNAs against ITGA3 (sc-35684) and ITGB1 (sc-35674), along with a nontargeting control siRNA (sc-37007), were obtained from Santa Cruz Biotechnology (Dallas, TX).

Techniques: Enzyme-linked Immunosorbent Assay, Binding Assay, Flow Cytometry, Transfection, Knockdown, Recombinant

( A ) ITGA3 mRNA expression in normal bladder tissues ( n = 18) and primary bladder tumors ( n = 408) based on TCGA data. ( B ) ITGA3 expression across consensus molecular subtypes of bladder cancer from five aggregated clinical cohorts. ( C ) Representative multiplex immunofluorescence images of TMA cores stained for ITGA3 (green), ITGB1 (red), and nuclei [DAPI (4′,6-diamidino-2-phenylindole), blue] of primary bladder carcinomas and normal tissues. Scale bars, 100 μm. ( D to F ) Quantification of ITGA3 expression in tumor versus normal tissues: fluorescence intensity (D), percentage of ITGA3 -positive cells (E), and H -scores (F). **** P < 0.0001.

Journal: Science Advances

Article Title: Phenotypic discovery and therapeutic evaluation of an ITGA3B1 -targeting antibody-drug conjugate for bladder cancer

doi: 10.1126/sciadv.ady0041

Figure Lengend Snippet: ( A ) ITGA3 mRNA expression in normal bladder tissues ( n = 18) and primary bladder tumors ( n = 408) based on TCGA data. ( B ) ITGA3 expression across consensus molecular subtypes of bladder cancer from five aggregated clinical cohorts. ( C ) Representative multiplex immunofluorescence images of TMA cores stained for ITGA3 (green), ITGB1 (red), and nuclei [DAPI (4′,6-diamidino-2-phenylindole), blue] of primary bladder carcinomas and normal tissues. Scale bars, 100 μm. ( D to F ) Quantification of ITGA3 expression in tumor versus normal tissues: fluorescence intensity (D), percentage of ITGA3 -positive cells (E), and H -scores (F). **** P < 0.0001.

Article Snippet: Target-specific siRNAs against ITGA3 (sc-35684) and ITGB1 (sc-35674), along with a nontargeting control siRNA (sc-37007), were obtained from Santa Cruz Biotechnology (Dallas, TX).

Techniques: Expressing, Multiplex Assay, Immunofluorescence, Staining, Fluorescence

Identification of signaling receptors required for S-phase progression. A , UM-SCC47 cells treated with vehicle alone or 30 μM SSTN EGFR for 3 h were lysed and subjected to immunoprecipitation with nonspecific, isotype-matched control IgG, and mAb 8G3 to Sdc4 or rabbit polyclonal antibody to Sdc2. Immunoprecipitates were probed for the presence of EGFR, α3 integrin (ITGA3), β4 integrin (ITGB4), phosphorylated ITGB4 with PY20, CD151, total and active RON (pY1238/1239), total and active ABL1 (pY412 and pY245), and Sdc2 and Sdc4; B , GST-S4ED immobilized on glutathione beads was incubated with UM-SCC47 whole-cell lysates overnight in the presence or absence of 30 μM His-tagged S2ED and the receptors captured by S4ED were analyzed by Western blot; C , Sdc4 immunoprecipitates from HaCaT whole-cell lysates were probed for associated α3 integrin (ITGA3), β4 integrin (ITGB4), EGFR, RON, and Sdc2 via Western blot. RON and Sdc2 levels in the total lysate are shown. D , model showing proposed order of receptor complex assembly. E , UM-SCC47 cells transfected for 72 h with siRNA specific for human EGFR (3′UTR), α3 integrin (ITA3; s7543), CD151 (s194332), or β4 integrin (ITGB4; s7584) before performing Sdc4 immunoprecipitation and probing for associated receptors. Protein expression in starting cell lysates is shown in <xref ref-type=Fig. S2 A . Results are representative of duplicate experiments with cells transfected with two different siRNA oligos for each targeted protein (see Fig. S2 B ); F , UM-SCC47 cells were treated for 72 h with either control siRNA (AM4635) or siRNA-specific anti-human Sdc4 (12434), β4 integrin (ITGB4; s7584), α3 integrin (ITGA3; s7543), EGFR (3′ UTR), CD151 (s194332), Sdc2 (s12635), RON (s8996), or ABL1 (s865), then labeled with EdU to quantify DNA synthesis; ∗∗∗ p ≤ 0.001. Western blot inset shows individual receptor expression 72 h after siRNA transfection. Results are representative of duplicate experiments with cells transfected with two different siRNA oligos for each targeted protein. EGFR, epidermal growth factor receptor; RON, recepteur d’origine nantais; Sdc2, syndecan-2; Sdc4, syndecan-4. " width="100%" height="100%">

Journal: The Journal of Biological Chemistry

Article Title: Plasma membrane proteoglycans syndecan-2 and syndecan-4 engage with EGFR and RON kinase to sustain carcinoma cell cycle progression

doi: 10.1016/j.jbc.2022.102029

Figure Lengend Snippet: Identification of signaling receptors required for S-phase progression. A , UM-SCC47 cells treated with vehicle alone or 30 μM SSTN EGFR for 3 h were lysed and subjected to immunoprecipitation with nonspecific, isotype-matched control IgG, and mAb 8G3 to Sdc4 or rabbit polyclonal antibody to Sdc2. Immunoprecipitates were probed for the presence of EGFR, α3 integrin (ITGA3), β4 integrin (ITGB4), phosphorylated ITGB4 with PY20, CD151, total and active RON (pY1238/1239), total and active ABL1 (pY412 and pY245), and Sdc2 and Sdc4; B , GST-S4ED immobilized on glutathione beads was incubated with UM-SCC47 whole-cell lysates overnight in the presence or absence of 30 μM His-tagged S2ED and the receptors captured by S4ED were analyzed by Western blot; C , Sdc4 immunoprecipitates from HaCaT whole-cell lysates were probed for associated α3 integrin (ITGA3), β4 integrin (ITGB4), EGFR, RON, and Sdc2 via Western blot. RON and Sdc2 levels in the total lysate are shown. D , model showing proposed order of receptor complex assembly. E , UM-SCC47 cells transfected for 72 h with siRNA specific for human EGFR (3′UTR), α3 integrin (ITA3; s7543), CD151 (s194332), or β4 integrin (ITGB4; s7584) before performing Sdc4 immunoprecipitation and probing for associated receptors. Protein expression in starting cell lysates is shown in Fig. S2 A . Results are representative of duplicate experiments with cells transfected with two different siRNA oligos for each targeted protein (see Fig. S2 B ); F , UM-SCC47 cells were treated for 72 h with either control siRNA (AM4635) or siRNA-specific anti-human Sdc4 (12434), β4 integrin (ITGB4; s7584), α3 integrin (ITGA3; s7543), EGFR (3′ UTR), CD151 (s194332), Sdc2 (s12635), RON (s8996), or ABL1 (s865), then labeled with EdU to quantify DNA synthesis; ∗∗∗ p ≤ 0.001. Western blot inset shows individual receptor expression 72 h after siRNA transfection. Results are representative of duplicate experiments with cells transfected with two different siRNA oligos for each targeted protein. EGFR, epidermal growth factor receptor; RON, recepteur d’origine nantais; Sdc2, syndecan-2; Sdc4, syndecan-4.

Article Snippet: Two different siRNAs were used for all treatments with equivalent results, paired with a scrambled siRNA control: Silencer Select control (AM4635) and target-specific siRNA oligos directed against human Sdc4 (siRNA ID# 12434, Target Sequence: 199 (ca)GGAATCTGATGACTTTGAG 217 and siRNA ID# s12638, Target Sequence: 536 CTACTGCTCATGTACCGTA(tt) 554 ; GenBank Accession number NM_002999.4), Sdc2 (siRNA ID# s12635, Target Sequence 996 TGACCTTGGAGAACGCAAA(tt) 1014 and siRNA ID# 12636 868 GACAGTCTGTTTAAACGGA(tt) 886 ; GenBank Accession Number NM_002998.4), ITGB4 (siRNA ID# s7584, Target Sequence: 658 GCGACTACACTATTGGATT(tt) 676 and siRNA ID# s7585, Target Sequence: 580 CCAACTCCATGTCCGATGA(tt) 598 ; GenBank Accession Number NM_001005731.3), ITGA3 (siRNA ID# s7543, Target Sequence: 1026 GGACTTATCTGAGTATAGT(tt) 1044 and siRNA ID# s7541, Target Sequence: 2629 GTAAATCACCGGCTACAAA(tt) 2647 ;GenBank Accession Number NM_002204.4), EGFR (3′UTR Target Sequence: 4905 TGCTCTGAAATCTCCTTTAtt 4923 , GenBank Accession Number NM_005228.5) and human EGFR-specific siRNA oligo (sc-29301) acquired from Santa Cruz Biotechnology, MST1R (siRNA ID# s8996, Target Sequence: 3576 GGCCCAGAATCGAATCCAA(tt) 3594 and siRNA ID# s8998, Target Sequence: 3065 GCGTAGATGGTGAATGTCA(tt) 3084 ; GenBank Accession Number, NM_002447.4), ABL1 (siRNA ID# s865, Target Sequence 2030 CGACAAGTGGGAGATGGAA(tt) 2048 and siRNA ID# s864, Target Sequence: 1836 GAAGGGAGGGTGTACCATT(tt) 1854 ; GenBank Accession Number NM_007313.3), and CD151 (siRNA ID# s2728, Target Sequence: 409 CTGCTGCGCCTGTACTTCA(tt) 428 and siRNA ID# s194332, 3′UTR Target Sequence: 935 CCCAACTACTGAGCTGAGA(tt) 953 ; GenBank Accession Number NM_004357.5)are from Life Technologies.

Techniques: Immunoprecipitation, Control, Incubation, Western Blot, Transfection, Expressing, Labeling, DNA Synthesis